December 3, 2021

$850,000 to save compounded hormones

We’ve rolled out plans for Phase 2 of our media campaign to save compounded hormone therapy — but it won’t happen without your support.

APC’s Board of Directors has approved plans for Phase 2 of the association’s three-year, $3 million campaign to save compounded hormones. Phase 2 requires $850,000 in funding — considerably less than last year’s extraordinary $1.5 million fundraising success.

But here’s the thing: This new phase can’t begin until that $850,000 is raised. The new year is coming fast, so the need to achieve that new fundraising goal is urgent.

Included in the 2022 plans are new campaign media featuring a prominent actress-spokesperson, a refresh of the compounding.com landing page and all advertising collateral, and a sharper focus on engaging prescribers — and their patients, too — in the campaign.

(Check out this video briefing on the 2022 cBHT Media Campaign plans.)

Yes, we’re asking you to give — for many of you, to give again — to support year two of this effort.

The good news: We already have about $150,000 pledged. With your continued support, we can make goal — and start this new phase of the campaign — in just a few weeks!

One big aim for 2022 focusing on educating prescribers of compounded hormones about the threat — and through those prescribers, reaching a patient base that doesn’t yet know that FDA may be planning to restrict their compounded hormone therapy.

One big aim for 2022 focusing on educating prescribers of compounded hormones about the threat — and through those prescribers, reaching a patient base that doesn’t yet know that FDA may be planning to restrict their compounded hormone therapy.

You and your relationships with prescribers will be key to that effort.

But we can’t do it without funding. Make your investment NOW.

And don’t forget: You’ll find all sorts of useful tools and resources for engaging patients and prescribers in this effort at A4PC.org/cbhttools.

Thanks. Together, we’ll save compounded hormone therapy and enrich the lives of millions of patients who benefit from it.